News · 26 weeks109+58%
2025-12-142026-06-07
Mix6590d
- Insider26(40%)
- SEC Filings20(31%)
- Other14(22%)
- Market3(5%)
- Earnings2(3%)
Latest news
25 items- PRMedicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European SubmissionPHILADELPHIA, June 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced the successful submission of a substantial modification application through the European Union Clinical Trials Information System (CTIS) supporting the planned Phase 2b study of Teverelix® in advanced prostate cancer (APC). The submission represents an important milestone in Medicus' strategy to advance Teverelix® toward registrational development focused on one of the largest unmet needs in prostate cancer treatment: pat
- SECSEC Form 424B3 filed by Medicus Pharma Ltd.424B3 - Medicus Pharma Ltd. (0001997296) (Filer)
- SECMedicus Pharma Ltd. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Medicus Pharma Ltd. (0001997296) (Filer)
- INSIDERSEC Form 4 filed by Chief Operating Officer Smith Andrew Alasdair4 - Medicus Pharma Ltd. (0001997296) (Issuer)
- INSIDERSEC Form 4 filed by Director Rodgers Cathy Mcmorris4 - Medicus Pharma Ltd. (0001997296) (Issuer)
- INSIDERSEC Form 4 filed by Director Raju Ajay4 - Medicus Pharma Ltd. (0001997296) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Mehmud Faisal4 - Medicus Pharma Ltd. (0001997296) (Issuer)
- INSIDERSEC Form 4 filed by Director May Sara R.4 - Medicus Pharma Ltd. (0001997296) (Issuer)
- INSIDERSEC Form 4 filed by Director Mahaffy Patrick J4 - Medicus Pharma Ltd. (0001997296) (Issuer)
- INSIDERSEC Form 4 filed by Director Kaiser Larry4 - Medicus Pharma Ltd. (0001997296) (Issuer)
- INSIDERSEC Form 4 filed by Director Fishman Barry4 - Medicus Pharma Ltd. (0001997296) (Issuer)
- INSIDERSEC Form 4 filed by Chief Scientific Officer Brennan Edward J.4 - Medicus Pharma Ltd. (0001997296) (Issuer)
- INSIDERSEC Form 4 filed by Director Ciaruffoli Robert J.4 - Medicus Pharma Ltd. (0001997296) (Issuer)
- INSIDERSEC Form 4 filed by President and CFO Bonner Carolyn F.4 - Medicus Pharma Ltd. (0001997296) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Bokhari Raza4 - Medicus Pharma Ltd. (0001997296) (Issuer)
- INSIDERSEC Form 4 filed by Director Ashton William4 - Medicus Pharma Ltd. (0001997296) (Issuer)
- PRMedicus Pharma Advances SkinJect® into Registrational Development for Gorlin SyndromePHILADELPHIA, June 03, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced the submission of Protocol SKNJCT-005 to the U.S. Food and Drug Administration (FDA) under the Company's existing Investigational New Drug (IND) application, for SkinJect® into registrational development for patients with Gorlin Syndrome, also called Nevoid Basal Cell Carcinoma Syndrome (NBCCS), a rare inherited genetic disorder associated with lifelong development of multiple basal cell carcinomas and recurrent skin cance
- PRMedicus Pharma Announces $22 Million Non-Dilutive FinancingPHILADELPHIA, May 28, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced that it has entered into a definitive financing agreement with an institutional investor providing for an up to $22 million structured financing facility. The financing is expected to increase the Company's pro forma cash position to approximately $30 million and provide a projected operating cash runway of more than twenty-four (24) months. Under the terms of the financing agreements, Medicus will receive $12 million
- SECMedicus Pharma Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - Medicus Pharma Ltd. (0001997296) (Filer)
- SECSEC Form 424B3 filed by Medicus Pharma Ltd.424B3 - Medicus Pharma Ltd. (0001997296) (Filer)
- PRMedicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate UpdatePHILADELPHIA, May 14, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today reported financial results for the three months ended March 31, 2026, and provided a corporate update highlighting continued execution across its SkinJect® and Teverelix® development programs. During the first quarter of 2026, Medicus continued to advance its transition into a diversified clinical-stage biotechnology company with active development programs in dermatologic oncology and urology/oncology, while replenishing its balanc
- SECSEC Form 10-Q filed by Medicus Pharma Ltd.10-Q - Medicus Pharma Ltd. (0001997296) (Filer)
- PRMedicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-ResponsePHILADELPHIA, May 06, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced results from a pre-specified expanded dataset analysis demonstrating positive dose response from its Phase 2 SKNJCT-003 study evaluating safety and efficacy of Doxorubicin Microneedle Array (D-MNA) to treat nodular basal cell carcinoma (BCC) of the skin, the most common type of skin cancer. These additional pre-specified analysis, build upon the previously reported positive topline results, provide expanded biological, his
- SECSEC Form DEF 14A filed by Medicus Pharma Ltd.DEF 14A - Medicus Pharma Ltd. (0001997296) (Filer)
- SECSEC Form 424B3 filed by Medicus Pharma Ltd.424B3 - Medicus Pharma Ltd. (0001997296) (Filer)
MDCX FAQ
4 questionsWhere does MDCX stock trade?
Medicus Pharma Ltd. (MDCX) is listed on NASDAQ.What sector and industry is MDCX in?
Medicus Pharma Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to MDCX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare MDCX side-by-side with any of them on Quantisnow.How can I track MDCX on Quantisnow?
Quantisnow aggregates Medicus Pharma Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MDCX to receive live email and push alerts on every new disclosure.